LSE - Delayed Quote USD

Moderna, Inc. (0A45.L)

167.05

0.00

(0.00%)

At close: July 21 at 6:35:42 PM GMT+1

Why vaccine makers aren't worried about Trump administration cuts

Vaccines have been a central focus for Trump's health leaders, but large-cap players aren't feeling the sting.

Yahoo Finance 12 hours ago

SNY

SNYNF

GLAXF
Moderna (NasdaqGS:MRNA) Sees 11% Share Price Surge Over Last Week

Moderna (NasdaqGS:MRNA) experienced a 10% share price increase, coinciding with broader market gains but slightly below the Nasdaq Composite's 5% rise. Despite the market being uplifted by strong earnings reports and easing tariff concerns, there were no specific events directly attributed to Moderna that week. While broader market trends contributed to the upward momentum, the company's price move was notably larger than the overall market increase of 4%. Such outperformance could have been...

Simply Wall St. 2 days ago

MRNA
Stocks to watch this week: Apple, Microsoft, Shell, HSBC, Lloyds and AstraZeneca

Earnings preview of key companies reporting next week and what to look out for.

Yahoo Finance UK 2 days ago

VSCFF

GBPEUR=X

GBP=X
Is Moderna Stock A Sell After Massive Job Cuts Wrack U.S. Health Agencies?

Moderna stock and other vaccine makers are under pressure after Peter Marks resigned from the FDA. Is MRNA stock a sell?

Investor's Business Daily 3 days ago

MRNA
Novavax slides after RFK Jr. casts doubts about COVID vaccine

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay. The Secretary of Health and Human Services pointed to the vaccine’s single-antigen composition as the reason for the push back, adding that the FDA is “shifting our priorities to multiple-antigen vaccines.” SHIFTING PRIORITIES: The Food and Drug Administration is sitting on the decision to grant full approval for Novavax COVID-19 shot. In an interview wit

TipRanks 16 days ago

PFE

NVAX

MRNA
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.

Robert F. Kennedy Jr. is the new Health Secretary. From fluoride, vaccines and beef tallow, here's how he might "go wild" on biotech stocks.

Investor's Business Daily 17 days ago

LLY

BIIB

MRNA
Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to report its first quarter 2025 financial results, and provide ...

ACCESS Newswire 17 days ago

MRNA
Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025

CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influenza, respiratory syncytial virus (RSV), cytomegalovirus ...

ACCESS Newswire 20 days ago

MRNA
Moderna (NasdaqGS:MRNA) Declines 19% Over A Week Amid Market Volatility

Moderna (NasdaqGS:MRNA) experienced a significant decline of 19% over the past week. This drop can largely be attributed to broader market turbulence, amplified by the steep fall in major indices such as the Dow, S&P 500, and Nasdaq, which collectively entered into correction or bear market territories due to escalating trade tensions and tariff uncertainties. As a biotechnology company, Moderna shares may have faced additional pressures amidst general concerns about economic growth and...

Simply Wall St. 21 days ago

MRNA
Moderna (NasdaqGS:MRNA) Takes 17% Hit Amid Global Trade Concerns

Moderna (NasdaqGS:MRNA) recently experienced a 17% decline in share price over the past week, a significant downturn that occurs amidst market-wide turbulence triggered by escalating global trade concerns, coupled with inflation and recession fears. While the broader market witnessed a 6% drop due to sweeping tariffs and economic uncertainties, Moderna's decline may have been aggravated by these macroeconomic factors affecting investor sentiment. The biotech sector, being particularly...

Simply Wall St. 23 days ago

MRNA
FDA delay on Novavax vaccine approval could be bellwether for vaccine sector: BofAS

The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has passed with no clarity on when the decision will move forward again.

Yahoo Finance 24 days ago

NVAX

JNJ

MRNA
Potential Stock Woe Ahead as Pfizer (PFE) Riles Donald Trump

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The pharmaceutical giant, best known for its COVID-19 products (Paxlovid and Comirnaty), Eliquis, and Prevnar, a pneumococcal vaccine, has been dealing with difficult year-over-year comps due to a withering COVID-19 portfolio. Moreover, many of Pfizer’s products, like Eliquis (2027 to 2029) and Ibrance (2027), face “patent cliffs.” That means their time for market exclusivity is

TipRanks 25 days ago

PFE

MRNA
Moderna (NasdaqGS:MRNA) Faces Legal Spotlight Affecting Investor Sentiment with -8% Dip Over Last Month

Recent legal challenges have put Moderna (NasdaqGS:MRNA) in a spotlight, as Genevant Sciences and Arbutus Biopharma Corporation have filed lawsuits alleging patent infringements related to lipid nanoparticle technology across numerous countries, affecting products like Spikevax®. This ongoing legal tussle has impacted investor sentiment, contributing to the company's share price decline of 8% over the month. Compounding this, general market trends showed volatility with a 3% decline. Despite...

Simply Wall St. 26 days ago

MRNA
Biotech stocks slide as Marks resignation seen being negative for sector

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit

TipRanks 26 days ago

GLPG

GLPGF

PTCT
Trending tickers: Tesla, Moderna, Newsmax, Johnson & Johnson and Travis Perkins

The latest investor updates on stocks that are trending on Tuesday.

Yahoo Finance UK 26 days ago

^DJI

GBPEUR=X

GBP=X
Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies'

Biotech stocks were hammered Monday after Peter Marks, a top FDA official, resigned amid a clash with Robert F. Kennedy Jr.

Investor's Business Daily 27 days ago

MRNA

PCVX

SRPT
Moderna, Rocket, Hut 8: Market Minute

Julie Hyman outlines the trending stories of the trading day on Market Minute. Moderna (MRNA) shares are falling after a top vaccine official from the Food and Drug Administration (FDA) resigned. Rocket (RKT) is acquiring Mr. Cooper (COOP) for $9.4 billion. Bitcoin (BTC=F) miner Hut 8 (HUT) is in focus on an announcement that it is partnering with the Trump family. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Yahoo Finance Video 27 days ago

COOP

MRNA

BTC=F
Stocks to Watch Monday: Mr. Cooper, Nvidia, Newsmax, Moderna

🔎 Rocket (RKT): The mortgage company agreed to buy Mr. Cooper (COOP) for $9.4 billion in an all-stock deal. Rocket shares dropped 7%, while those in the target jumped 14%. ↘️ Nvidia (NVDA): The AI chip stock sold off, as did shares of CoreWeave (CRWV), the Nvidia-backed startup that went public last week.

The Wall Street Journal 27 days ago

RKT

TSLA

MRNA
Moderna, biotech stocks slide following resignation of FDA official Peter Marks

The resignation of one of the FDA's top officials, Peter Marks, is worrying Wall Street as they await a replacement.

Yahoo Finance 27 days ago

DVAX

PCVX

NVAX
Moderna shares drop amid FDA leadership change

Moderna (MRNA) shares dropped nearly 12% following news that FDA official Peter Marks will step down on April 5th, causing uncertainty in the biotech sector, particularly for vaccine makers. Yahoo Finance Senior Reporter Anjalee Khemlani joins Morning Brief to discuss how this leadership change could impact companies like Moderna, Novavax (NVAX), and others in the healthcare industry. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.

Yahoo Finance Video 27 days ago

NVAX

MRNA

Performance Overview

Return	0A45.L	MSCI WORLD (^990100-USD-STRD)
YTD	+321.84%	-2.31%
1-Year	+54.86%	--
3-Year	+16.68%	+26.57%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Moderna, Inc. (0A45.L)

Why vaccine makers aren't worried about Trump administration cuts

Moderna (NasdaqGS:MRNA) Sees 11% Share Price Surge Over Last Week

Stocks to watch this week: Apple, Microsoft, Shell, HSBC, Lloyds and AstraZeneca

Is Moderna Stock A Sell After Massive Job Cuts Wrack U.S. Health Agencies?

Novavax slides after RFK Jr. casts doubts about COVID vaccine

Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.

Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025

Moderna (NasdaqGS:MRNA) Declines 19% Over A Week Amid Market Volatility

Moderna (NasdaqGS:MRNA) Takes 17% Hit Amid Global Trade Concerns

FDA delay on Novavax vaccine approval could be bellwether for vaccine sector: BofAS

Potential Stock Woe Ahead as Pfizer (PFE) Riles Donald Trump

Moderna (NasdaqGS:MRNA) Faces Legal Spotlight Affecting Investor Sentiment with -8% Dip Over Last Month

Biotech stocks slide as Marks resignation seen being negative for sector

Trending tickers: Tesla, Moderna, Newsmax, Johnson & Johnson and Travis Perkins

Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies'

Moderna, Rocket, Hut 8: Market Minute

Stocks to Watch Monday: Mr. Cooper, Nvidia, Newsmax, Moderna

Moderna, biotech stocks slide following resignation of FDA official Peter Marks

Moderna shares drop amid FDA leadership change

Performance Overview